Improving Signal Detection in Schizophrenia Trials: Challenges and Approaches

In the complex landscape of schizophrenia research, detection of therapeutic signals demands specialized expertise and rigorous methodology. 

This recent review from leading experts highlights how data quality significantly impacts trial outcomes. Measurement inconsistencies—particularly in negative symptom assessment—can obscure potential treatment effects, while rater training, standardized interview techniques, and advanced monitoring systems demonstrably improve signal detection.

Read the full article to gain insights into optimizing clinical trial data quality and advancing schizophrenia research.

This review article was originally published in the Journal of Schizophrenia Research (Volume 10, Issue 1, February 2024). The authors, David Daniel, Jean Busner, and Adam Kott, are clinical scientists at Signant Health with expertise in schizophrenia assessment and clinical trial methodology.